Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03257033 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03257033 · ClinicalTrials.gov record · last posted 2026-08-24

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Name: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC — clinical trial record (NCT03257033)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TIGeR-PaC

StatusRecruiting

PhasePhase 3

SponsorRenovoRx

Started2018-03-12

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Protocol amendment history 2 changes detected by DataLookout

2026-08-25

Primary completion pushed: 2026-06 → 2027-06

2026-08-25

Completion pushed: 2026-09 → 2027-09

Trial Details

NCT Number	NCT03257033
Lead Sponsor	RenovoRx
Conditions	Locally Advanced Pancreatic Cancer
Enrollment	190 participants
Start Date	2018-03-12
Primary Completion	2027-06 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-08-24